GSK (LON:GSK) Shares Break Below 50-Day Moving Average – Here’s What Happened

GSK plc (LON:GSK)’s share price crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of GBX 1,849.02 and traded as low as GBX 1,783.50. GSK shares last traded at GBX 1,822.50, with a volume of 52,664,949 shares trading hands.

Analyst Ratings Changes

GSK has been the topic of several research analyst reports. Berenberg Bank increased their price objective on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, October 20th. Royal Bank Of Canada assumed coverage on GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 target price for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Thursday. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Trading Up 2.0%

The company has a market capitalization of £74.13 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28. The company has a debt-to-equity ratio of 126.38, a current ratio of 0.86 and a quick ratio of 0.73. The company’s fifty day moving average is GBX 1,845.48 and its 200-day moving average is GBX 1,948.89.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. The firm had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. On average, analysts anticipate that GSK plc will post 175.98 EPS for the current fiscal year.

Insider Activity

In other news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction on Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Insiders acquired 2,151 shares of company stock worth $6,021,921 in the last quarter. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.